Quercetin Allergic Rhinitis Meta-Analysis: IgE and Histamine Suppression as a Spring Allergy Option
WELLNESS

Quercetin Allergic Rhinitis Meta-Analysis: IgE and Histamine Suppression as a Spring Allergy Option

By Mira · · https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1673712/full
KO | EN

As spring pollen allergy season begins, a systematic review and meta-analysis comprehensively examining quercetin’s effects on allergic rhinitis was published in Frontiers in Pharmacology. The review consistently validates multi-target anti-allergic mechanisms in animal models, establishing the scientific foundation for supplement options.

Meta-analysis core results

Total IgE reduction: Quercetin meaningfully reduced expression of total IgE, the core allergy antibody.

OVA-specific IgE reduction: Antigen-specific IgE also reduced. Targeted suppression of allergic response.

Histamine suppression: Reduction of histamine, the core mediator of allergic symptoms.

Inflammatory cell infiltration suppression: Reduced mucosal infiltration of eosinophils, macrophages, and lymphocytes.

Th1/Th2 balance: Adjusted Th2 dominance toward Th1. Treg/Th17 balance also restored.

Clinical data

Human trials remain limited beyond animal models, but meaningful data exists.

Multicomponent nutraceutical trial: In adults with grass pollen allergic rhinitis, quercetin + perilla + vitamin D3 added to standard therapy produced 39% greater symptom improvement vs standard therapy alone.

Pediatric seasonal allergic rhinitis pilot: A multicomponent supplement of quercetin Phytosome® + zinc + vitamin C reported favorable effects in pediatric seasonal allergic rhinitis management.

Monotherapy trials: Two trials evaluated quercetin monotherapy. Reported symptom reduction and quality of life improvement. Larger randomized trials needed.

Mechanism

Mast cell stabilization: Suppression of histamine, leukotriene, and cytokine release from mast cells.

Inflammation signal blocking: Partial inhibition of NF-κB, MAPK, and other inflammatory signaling pathways.

Oxidative stress reduction: Reduction of oxidative stress accompanying chronic allergy.

Th cell balance: Normalization of Th1/Th2 ratio. Mitigation of Th2-dominant allergy patterns.

Treg restoration: Restored function of regulatory T cells. Improved allergic self-regulation.

Quercetin forms and absorption

Standard quercetin: Low absorption (1~2%). Difficult to achieve consistent clinical effect.

Phytosome®: Bound to phospholipids. 20x+ improved absorption. Mainly used in trials.

Dihydroquercetin (taxifolin): More stable form. Some data.

EMIQ (isoquercitrin): Enzyme-modified for improved absorption. Mainstream in Japanese market.

Verifying form on the label is key. Standard quercetin makes clinical effect prediction difficult.

Dose and timing

Seasonal allergy prevention: Start 2~4 weeks before season.

Symptom management: 200~500 mg/day (Phytosome equivalent). With meals.

Multicomponent combinations: Synergy with vitamin C, zinc, perilla extract, vitamin D3.

Duration: Continue through season. Break possible after season ends.

Who fits

Seasonal allergic rhinitis: Additional option to standard therapy (antihistamines, nasal steroids).

Mild chronic allergy: First-line adjunct. On the foundation of environmental avoidance and nasal lavage.

Complex allergy patterns: Adjunct for populations with food allergy or atopic comorbidities.

Drug side effect concerns: Populations seeking to avoid antihistamine drowsiness or nasal steroid burden.

Pediatric seasonal allergy: Some clinical data in multicomponent supplement form.

Cautions

Drug interactions: Possible interactions with warfarin, cyclosporine, certain anticancer drugs. Consult a clinician.

Pregnancy/breastfeeding: Insufficient safety data. Avoid.

Severe allergy: Not for monotherapy. With standard therapy (antihistamines, nasal steroids, immunotherapy).

Anaphylaxis history: Cannot be managed with supplements alone. Emergency drugs (epinephrine) priority.

Thyroid disease: Some data suggest possible thyroid effects. Consult a clinician.

Spring 2026 implications

The meta-analysis published as spring allergy season starts is meaningful. Quercetin doesn’t replace traditional antihistamines, but adds synergy to standard therapy through multi-target mechanisms.

The same period’s polyphenol meta-analysis (JACI: In Practice 2025) also reported clinical effects of polyphenol compounds in allergic rhinitis, accumulating evidence for natural anti-allergic options.

Daily guide

Pre-season preparation: Start Phytosome form 200~500 mg/day 2~4 weeks before spring season.

Combinations: With vitamin C 500~1,000 mg, zinc 15~30 mg, vitamin D3 1,000~2,000 IU (25~50μg).

Environmental avoidance: Avoid outdoor exposure during high pollen times (5~10 AM). Use HEPA filters.

Nasal lavage: Saline nasal washes to remove mucosal allergens.

Standard therapy parallel: Use OTC antihistamines (cetirizine, loratadine) when symptoms are strong.

Post-season: Supplement break. Restart before next season.

Allergy is the immune system’s misrecognition. Quercetin is a tool to gently adjust that recognition. As an adjunct option on the foundation of environmental avoidance and standard therapy.